Safety of tumor necrosis factor inhibitor use in patients with concomitant malignancy

BACKGROUND/AIMS: Safety for tumor necrosis factor inhibitors (TNFi) in cancer has been focused on risk of incident malignancies, but studies on prognostic effects have been scarce. We determined survival and recurrence rates at 1, 2, and 5 years after cancer diagnosis in patients with and without co...

Descripción completa

Detalles Bibliográficos
Autores principales: Phan, Hiep, Weideman, Rick A., Cipher, Daisha J., Feagins, Linda A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385568/
https://www.ncbi.nlm.nih.gov/pubmed/32252501
http://dx.doi.org/10.5217/ir.2019.09140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385568/
https://www.ncbi.nlm.nih.gov/pubmed/32252501
http://dx.doi.org/10.5217/ir.2019.09140

Ejemplares similares